Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system
IntroductionIn 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS). Differently from ocrelizumab, that is adminis...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2024-06-01
|
| シリーズ: | Frontiers in Neurology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1383910/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|